<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8A84268719AB4948BDDF43F3155FF533" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5646 IH: Restoring Safeguards for Dangerous Abortion Drugs Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-09-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5646</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250930">September 30, 2025</action-date><action-desc><sponsor name-id="M001211">Mrs. Miller of Illinois</sponsor> (for herself, <cosponsor name-id="M001212">Mr. Moore of Alabama</cosponsor>, <cosponsor name-id="B001325">Mrs. Biggs of South Carolina</cosponsor>, <cosponsor name-id="W000814">Mr. Weber of Texas</cosponsor>, <cosponsor name-id="H001101">Mr. Harrigan</cosponsor>, <cosponsor name-id="B001309">Mr. Burchett</cosponsor>, and <cosponsor name-id="L000578">Mr. LaMalfa</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes.</official-title></form><legis-body id="H24DD405F61C542B4A1C6AFA68A953B0E" style="OLC"> 
<section id="HCCB3E1823CBD4A1B81B08E8B90760498" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Restoring Safeguards for Dangerous Abortion Drugs Act</short-title></quote>.</text></section> <section commented="no" display-inline="no-display-inline" id="HE70104BB59AC473CA74E5642238BC0C7"><enum>2.</enum><header>Definition</header><text display-inline="no-display-inline">In this Act, the term <term>covered medication</term> means mifepristone, also known by the brand names, Mifeprex and Korlym, and the developmental code name, RU–486.</text></section> 
<section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="H9792E99772EE4667BC5D8B0317A55560"><enum>3.</enum><header display-inline="yes-display-inline">Mifepristone REMS</header> 
<subsection commented="no" display-inline="no-display-inline" id="H9CE49E2317224A049807696C3E420A1C"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services shall—</text> <paragraph id="HBE1A3B73B5D44000A82E7965E5A7680E"><enum>(1)</enum><text>withdraw approval of the risk evaluation and mitigation strategy pursuant to section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) for the covered medication that is in effect on the date of enactment of this Act; and</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H6BF7EE70FB5E4CE8A9426ACD43D75EFC"><enum>(2)</enum><text>approve a risk evaluation and mitigation strategy for the covered medication that is identical to the risk evaluation and mitigation strategy for such covered medication that was approved by such Secretary in June 2011.</text></paragraph></subsection> <subsection commented="no" display-inline="no-display-inline" id="H3C7724D970F944E0829689EC154953E0"><enum>(b)</enum><header>Restriction</header><text>Notwithstanding any provision of section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>), the Secretary of Health and Human Services—</text> 
<paragraph commented="no" display-inline="no-display-inline" id="HFD75DAEE004D4A8AAFAC7C8CF1BBE6F9"><enum>(1)</enum><text display-inline="yes-display-inline">shall require a risk evaluation and mitigation strategy pursuant to such section 505–1 for the covered medication; and</text></paragraph> <paragraph commented="no" display-inline="no-display-inline" id="H0F7BDDD104CB42A29C46A4CC41B2828C"><enum>(2)</enum><text display-inline="yes-display-inline">may not approve a risk evaluation and mitigation strategy pursuant to such section for the covered medication that is different from the strategy described in subsection (a)(2).</text></paragraph></subsection></section> 
<section commented="no" display-inline="no-display-inline" id="HFE90BB935F7841EAB7B371715E45139A"><enum>4.</enum><header>Federal tort for harm to women caused by abortion drugs</header> 
<subsection commented="no" display-inline="no-display-inline" id="H41BE41C0912C48AF8C640CB2067B3D9D"><enum>(a)</enum><header>Definition</header><text>In this section, the term <term>covered entity</term> means a telehealth provider, pharmacy, or any other person who knowingly imports or transports a covered medication in interstate or foreign commerce in violation of section 1462 of title 18, United States Code.</text></subsection> <subsection id="HF5B1604122FE48329FCCE8FCDFC6CA57"><enum>(b)</enum><header>Liability</header><text>A covered entity shall be liable in accordance with this section to any individual who suffers bodily injury or harm to mental health (including any physical, psychological, emotional, or physiological harm) that is attributable, in whole or in part, to the individual’s use of a covered medication imported or transported as described in subsection (a). </text></subsection> 
<subsection id="HA8B794588A17446994A988480A7821A0"><enum>(c)</enum><header>Private right of action</header><text>An individual who suffers bodily injury or harm to mental health that is attributable, in whole or in part, to the individual’s use of a covered medication as described in subsection (b) may bring a civil action against the covered entity in an appropriate district court of the United States or a State court of competent jurisdiction for—</text> <paragraph id="H9286904D55AE4D5A9B989F758EDDE585"><enum>(1)</enum><text>compensatory damages;</text></paragraph> 
<paragraph id="H7FDC76194B9A4F17BC44C01AB6EB14FB"><enum>(2)</enum><text>punitive damages; and</text></paragraph> <paragraph id="HB0B2EDF62A944B4AA584B485AB7CA894" commented="no" display-inline="no-display-inline"><enum>(3)</enum><text>attorney’s fees and costs.</text></paragraph></subsection> 
<subsection id="HC44BD660D5A146EDB524BC3F7162B7B0"><enum>(d)</enum><header>Rules of construction</header><text display-inline="yes-display-inline">Nothing in this section shall be construed to preempt any State law that makes available any other remedy to an individual described in subsection (b).</text></subsection> <subsection id="H1F1E5AD343484AF1A9257E02A37C0891"><enum>(e)</enum><header>Effective date</header><text display-inline="yes-display-inline">This section shall take effect on the date that is 90 days after the date of enactment of this Act.</text></subsection></section> 
<section commented="no" display-inline="no-display-inline" id="HFDACFF5D76524E04BA3C6437F7CD055A"><enum>5.</enum><header>Ban on importation</header><text display-inline="no-display-inline">Section 801 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381</external-xref>) is amended—</text> <paragraph commented="no" display-inline="no-display-inline" id="HC17E409F3A814EBDAE2CF1B708D28DFD"><enum>(1)</enum><text display-inline="yes-display-inline">in the third sentence of subsection (a), by inserting <quote>or is mifepristone,</quote> after <quote>under section 569D,</quote>; and</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H036476A9E6CB4999A413FB9B7AC4E8D3"><enum>(2)</enum><text>in subsection (d)(1), by adding at the end the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="HD0D09621F1074C329A6B41AF62F13ABF"> <subparagraph id="H6A29D27405A7474CB63779C057C4FF38" indent="up1"><enum>(C)</enum><text>Notwithstanding any other provision of law, no person may import the drug mifepristone into the United States, including by mailing such drug to individuals.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> 
</legis-body></bill>

